September 11, 2017
A study led by UNC Lineberger's Stacie Dusetzina, PhD, compared the cost of the generic and brand-name version of capecitabine, which was one of the first high-priced chemotherapy pills to come off patent in the United States. Their findings offer a glimpse into what could be happening with generic competition in this specialty drug market.
August 11, 2017
UNC Gillings School of Global Public Health has appointed UNC Lineberger's Kurt Ribisl, PhD, as chair of its health behavior department.
August 9, 2017
UNC Lineberger's Donald Rosenstein, MD, director of the UNC Comprehensive Cancer Support Program, was elected to lead the American Psychosocial Oncology Society.
July 26, 2017
The Carolina Cancer Screening Initiative, led by Daniel S. Reuland, MD, MPH, brings together UNC Lineberger’s clinicians and public health researchers with community partners to implement evidence-based cancer screening programs to reduce cancer burden among North Carolinians.
July 25, 2017
A study led by UNC Lineberger's Jennifer Smith, PhD, professor of epidemiology at the UNC Gillings School of Global Public Health, found that among a group of 429 women who did not undergo routine cervical cancer screenings, two-thirds used and returned an in-home self-test, and 15 percent tested positive for human papillomavirus.
June 21, 2017
A study published in the Journal of the American Medical Association, and co-authored by UNC Lineberger member Deborah Tate, PhD, communicated the results of an internet-based weight loss program in low-income women in the year after giving birth. By helping new mothers return to their pre-pregnancy weights, they hope to lower their risk for obesity and chronic diseases, such as cancer.
June 5, 2017
UNC Lineberger researchers led by Ronald C. Chen, MD, MPH, surveyed 1,171 men diagnosed with prostate cancer in North Carolina, finding that while both white and black men were concerned about curing their cancer and the quality-of-life impacts of treatment, more black men considered other social and personal factors -- such as recovery time and cost -- to be very important in their treatment decision-making.
June 4, 2017
A study presented by Ethan Basch, MD, MSc, at the American Society of Clinical Oncology is the first to find a survival benefit for patient reported outcomes.
June 1, 2017
In preliminary findings presented at the American Society of Clinical Oncology Annual Meeting 2017, researchers show that when physicians had to choose between multiple, on-patent drugs for metastatic kidney cancer and chronic myeloid leukemia, they were more likely to prescribe drugs from companies they had received general payments from.
May 15, 2017
UNC Lineberger researchers led by Dan Reuland, MD, MPH, report in JAMA Internal Medicine that providing one-on-one support and customized tools for decision-making increased screening rates for patients at two community health centers in North Carolina and New Mexico.
